Abbokinase

Name: Abbokinase

US Brand Name

  1. Abbokinase
  2. Kinlytic

Descriptions

Urokinase injection is used to dissolve blood clots that have formed in the lungs (pulmonary embolism).

This medicine was available only with your doctor's prescription.

This medicine is not available in the United States as of October 2010.

This product is available in the following dosage forms:

  • Powder for Solution

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of urokinase injection in the pediatric population. Safety and efficacy have not been established.

Geriatric

No information is available on the relationship of age to the effects of urokinase injection in geriatric patients.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

  • Bleeding problems or a history of bleeding in any part of the body or
  • Blood vessel problems (e.g., aneurysm) or
  • Brain disease or tumor or
  • Hypertension (high blood pressure), uncontrolled or
  • Stroke, recent (within two months) or
  • Surgery or injury to the brain or spine, recent (within two months) or
  • Trauma including CPR (cardiopulmonary resuscitation), recent—Should not be used in patients with these conditions.
  • Blood clotting disorders or
  • Diabetic eye problems (e.g., hemorrhagic retinopathy) or
  • Heart disease or infections (e.g., endocarditis, mitral stenosis) or
  • Injections into a blood vessel or
  • Kidney disease, severe or
  • Liver disease, severe or
  • Placement of any tube into the body or
  • Surgery or injury of any kind, major and recent—The chance of serious bleeding may be increased.
  • High cholesterol, history of—The chance of having a serious side effect may be increased.

For the Consumer

Applies to urokinase: intravenous powder for solution

Along with its needed effects, urokinase (the active ingredient contained in Abbokinase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking urokinase:

More common
  • Bleeding gums
  • coughing up blood
  • difficulty with breathing or swallowing
  • dizziness
  • headache
  • increased menstrual flow or vaginal bleeding
  • nosebleeds
  • paralysis
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • shortness of breath
Rare
  • Cough
  • fast heartbeat
  • hives or welts
  • itching skin
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the skin
  • skin rash
  • tightness in the chest
  • unusual tiredness or weakness
  • wheezing
Incidence not known
  • Blue lips and fingernails
  • blurred vision
  • chest pain or discomfort
  • confusion
  • convulsions
  • coughing that sometimes produces a pink frothy sputum
  • difficult, fast, or noisy breathing, sometimes with wheezing
  • fainting
  • fast, irregular, pounding, or racing heartbeat or pulse
  • inability to speak
  • increased sweating
  • low blood pressure or pulse
  • numbness or tingling in the face, arms, or legs
  • pale skin
  • severe or sudden headache
  • severe or sudden weakness in the arm or leg on one side of the body
  • slurred speech
  • swelling in the legs and ankles
  • trouble with walking or speaking
  • unconsciousness

Liver Dose Adjustments

Data not available

Urokinase Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed. US FDA pregnancy category: B

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

(web3)